Calendrier des promotions Gilead Sciences
Calendrier avancé
Graphique simple
À propos de l'entreprise Gilead Sciences
Gilead Sciences, Inc., биофармацевтическая компания, основанная на исследованиях, обнаруживает, разрабатывает и продает лекарства для удовлетворения неудовлетворенных медицинских потребностей в США, Европе и на международном уровне. Компания предоставляет продукты Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera / Eviplera, Stribild и Atripla для лечения инфекции, вызванной вирусом иммунодефицита человека (ВИЧ); Веклуры, инъекция для внутривенного введения, для лечения коронавирусной болезни 2019; и Epclusa, Harvoni, Vosevi, Vemlidy и Viread для лечения заболеваний печени. plus de détailsParamètres de base
IPO date
1992-01-22
ISIN
US3755581036
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
2.78
Дивиденд ао
0.79
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 4.02 | 4 |
| P/BV | 6 | 2 |
| P/E | 240.57 | 1 |
Efficacité
| Nom | Signification | Grade |
| ROA | 0.7926 | 1 |
| ROE | 2.28 | 1 |
| ROIC | 11.06 | 4 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 3.16 | 7.9 |
| DSI | 0.9286 | 9.29 |
| Croissance moyenne du dividende | 4.04 | 6.74 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 6.02 | 0 |
| Debt/Ratio | 0.4528 | 10 |
| Debt/Equity | 2.07 | 6 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 16.46 | 3 |
| Rentabilité Ebitda, % | -47.9 | 0 |
| Rentabilité EPS, % | 442.51 | 10 |
Dividendes
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 112.05 $ | 0 $ | 0 $ | -1.85 % | 0 % | 0 % |
| common.calendar.number_days.7d | 110.46 $ | 109.98 $ | 112.05 $ | -0.43 % | 0 % | 0 % |
| common.calendar.number_days.30d | 106.74 $ | 106.74 $ | 113 $ | 3.04 % | 0 % | 0 % |
| common.calendar.number_days.90d | 105.25 $ | 96.91 $ | 113 $ | 4.49 % | 0 % | 0 % |
| common.calendar.number_days.180d | 97.99 $ | 89.14 $ | 117.41 $ | 12.24 % | 0 % | 0 % |
| common.calendar.number_days.1y | 77 $ | 63.15 $ | 117.41 $ | 42.83 % | 0 % | 0 % |
| common.calendar.number_days.3y | 63.82 $ | 58.53 $ | 117.41 $ | 72.33 % | 0 % | 0 % |
| common.calendar.number_days.5y | 65.28 $ | 56.65 $ | 117.41 $ | 68.47 % | 0 % | 0 % |
| common.calendar.number_days.10y | 72.78 $ | 56.65 $ | 122.21 $ | 51.11 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 105.96 $ | 89.14 $ | 117.41 $ | 3.79 % | 0 % | 0 % |
Délit d'initié
Principaux propriétaires
Contenu dans l'ETF
ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
| Future Tech ETF | 8.5029 | -18.13 | 0.35 |
| Principal Healthcare Innovators ETF | 8.5029 | -3.92 | 0.35 |
| iShares Evolved U.S. Innovative Healthcare ETF | 4.1 | 0.000586 | 0.18 |
| Pacer BioThreat Strategy ETF | 3.56666 | 6.83 | 0.7 |
| 2nd Vote Life Neutral Plus ETF | 3.36 | 0 | 0.75 |
| Donoghue Forlines Innovation ETF | 1.90015 | 18.15 | 0.69 |
| John Hancock Multifactor Healthcare ETF | 1.62 | 29.34 | 0.40 |
| FCF US Quality ETF | 1.49429 | 9.78 | 0.59 |
| Nationwide Maximum Diversification U.S. Core Equity ETF | 1.3 | 26.65 | 0.34 |
| VanEck Morningstar Global Wide Moat ETF | 1.0755 | 11.32 | 0.52 |
| Nationwide Nasdaq-100 Risk-Managed Income ETF | 0.71563 | 3.32 | 0.68 |
| JPMorgan Corporate Bond Research Enhanced ETF | 0.41 | 1.94 | 0.09 |
| iShares Morningstar Large-Cap Value ETF | 0.40345 | 53.47 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.3637 | -3.6 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.20825 | 184.21 | 0.03 |
| 2,5 | 21,29 | 0,42 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Andrew D. Dickinson | Chief Financial Officer | 2.66M | 1970 (55 années) |
| Ms. Johanna Mercier | Chief Commercial Officer | 3.1M | 1970 (55 années) |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 2.79M | 1963 (62 année) |
| Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations | N/A | |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | N/A | 1977 (48 années) |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | N/A | 1962 (63 année) |
| Ms. Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | 1967 (58 années) |
| Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe | N/A | 1946 (79 années) |
| Mr. Daniel P. O'Day | Chairman & CEO | 1964 (61 année) | |
| Ms. Deborah H. Telman | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 1965 (60 années) |
Informations sur l'entreprise
Adresse: United States, Foster City, 333 Lakeside Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: http://www.gilead.com
Site web: http://www.gilead.com
